Jackie Papkoff
Plus aucun poste en cours
Profil
Jackie Papkoff served as Chief Scientific Officer at CFD Therapeutics, Inc., Senior VP & Chief Scientific Officer-Microbiome at Assembly Biosciences, Inc., Senior Vice President-Research at Evelo Biosciences, Inc., and Vice President-Immunology Scientific Innovation at California Innovation Center.
Papkoff holds a doctorate degree from The Salk Institute for Biological Studies and the University of California San Diego, and an undergraduate degree from the University of California, Santa Cruz.
Anciens postes connus de Jackie Papkoff
Sociétés | Poste | Fin |
---|---|---|
California Innovation Center | Corporate Officer/Principal | - |
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | - |
EVELO BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | - |
CFD Therapeutics, Inc.
CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Directeur Technique/Scientifique/R&D | - |
Formation de Jackie Papkoff
The Salk Institute for Biological Studies | Doctorate Degree |
University of California San Diego | Doctorate Degree |
University of California, Santa Cruz | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
CFD Therapeutics, Inc.
CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Health Technology |
California Innovation Center |